<DOC>
	<DOCNO>NCT00066365</DOCNO>
	<brief_summary>RATIONALE : Inhaling aerosolize sargramostim surgery may interfere growth tumor cell shrink tumor remove surgery . Sargramostim may kill tumor cell remain surgery . This may effective treatment osteosarcoma spread lung . PURPOSE : This phase II trial study well inhale sargramostim work treat patient undergo surgery first recurrence osteosarcoma spread lung .</brief_summary>
	<brief_title>Inhaled Sargramostim Treating Patients With First Pulmonary ( Lung ) Recurrence Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess histological finding patient first pulmonary recurrence osteosarcoma undergo resection pulmonary metastasis treatment 2 course aerosolize sargramostim ( GM-CSF ) . - Determine event-free survival patient treated drug . - Determine whether maximum tolerate dose trial inhale GM-CSF adult patient melanoma tolerable pediatric patient . Secondary - Determine effect specific thoracic surgical management outcome patient treat drug . OUTLINE : This multicenter , dose escalation study . Patients assign 1 2 group accord extent pulmonary recurrence ( unilateral bilateral ) . - Group I ( unilateral recurrence ) : - Initial inhalation therapy : Patients receive inhale sargramostim ( GM-CSF ) twice daily day 1-7 . Treatment repeat every week every 14 day total 2 course . - Thoracotomy : Patients undergo thoracotomy day 22 . - Post-thoracotomy inhalation therapy : Beginning day 29 , soon possible thereafter , patient resume inhalation therapy 12 additional course . - Group II ( bilateral recurrence ) : Patients may enrol study either first thoracotomy . - First thoracotomy : Patients undergo unilateral thoracotomy . - Initial inhalation therapy : Patients receive inhale GM-CSF , soon possible recovery first thoracotomy , twice daily day 1-7 . Treatment repeat every week every 14 day total 2 course . - Contralateral thoracotomy : Patients undergo contralateral thoracotomy day 22 . - Post-thoracotomy inhalation therapy : Beginning day 29 , soon possible , patient resume inhalation therapy 12 additional course . Treatment group continue absence disease progression unacceptable toxicity . Patients follow every 2 month 1 year , every 4 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study within 1.6-2 year .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm osteosarcoma primary diagnosis Lesions detect least 1 lung consistent metastatic disease approachable thoracotomy No prior recurrence osteosarcoma No sit metastasis Resectable pulmonary nodule ( ) , define nodule ( ) removable without perform pneumonectomy ( e.g. , nodule immediately adjacent main stem bronchus main pulmonary vessel ) Prior thoracotomy allow patient image consistent metastatic involvement lung provide lung thoracotomy perform diseasefree No pleural effusion pleural base nodule PATIENT CHARACTERISTICS : Age 39 Performance status Karnofsky 50100 % ( patient 16 year age ) Lansky 50100 % ( patient 16 year age ) Life expectancy At least 8 week Hematopoietic Not specify Hepatic Not specify Renal Not specify Pulmonary No evidence dyspnea rest No exercise intolerance Pulse oximetry least 94 % Baseline Forced expiratory volume 1 second ( FEV_1 ) least 80 % predict No history asthma No history reactive airway disease No history bronchospasm Other Willing able perform inhalation therapy No medical contraindication surgical excision Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy No concurrent immunomodulating agent Chemotherapy No concurrent anticancer chemotherapy Endocrine therapy No concurrent steroid route Radiotherapy Not specify Surgery See Disease Characteristics No concurrent thoracoscopy videoassisted thoracic surgery Other No 1 prior treatment regimen osteosarcoma No concurrent participation another COG therapeutic study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>lung metastasis</keyword>
</DOC>